We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Genflow Biosciences Plc | GENF | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.55 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.55 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 24/4/2024 06:47 by moneymunch Genflow Biosciences (LON:GENF) (OTCQB:GENFF)1,585 followers 18h Safety paramount in the #biotech industry, and at Genflow Biosciences (LON:GENF) (OTCQB:GENFF), it's our top priority. We're proud to have developed patent-pending technology to enhance safety in our #SIRT6 studies. It is this unwavering commitment to safety that has allowed us to advance a number of our studies to the pre-clinical/develop Learn more about Genflow's innovative studies & exciting investment thesis: #GENF #aging #healthspan #NASH #genetherapy Investors – Genflow Bioscience |
Posted at 13/4/2024 08:35 by moneymunch 10th - 11th June 2024 - Organised by Longevity Technology who hold 3%. Gla ;-)New international event program launches to bring longevity entrepreneurs and investors together. Founders Forum and Longevity.Technology today announced the launch of the Founders Longevity Forum, a premier event series designed to educate and connect investors with the vast potential within the longevity market. The inaugural Founders Longevity Forum will take place at Olympia London during the renowned London Tech Week, focusing on a sector that is projected to exceed $600 billion by 2025. This partnership aims to foster meaningful connections between startups, venture capitalists (VCs), corporate venture capitalists (CVCs), family offices and CEOs leading the charge in longevity. Brent Hoberman, Co-Founder and Executive Chair of Founders Forum Group, said: “Longevity is becoming a mega trend as science makes increased healthspans more realistic, converging with a wider shift towards preventative healthcare. “We’ve noticed a need to connect top scientists and innovative startups with funds to help them turn their dreams into reality. By bringing together the best and brightest minds working on longevity today, we can galvanize progress in this area and transform the demographic landscape.” Taking place on New international event program launches to bring longevity entrepreneurs and investors together.4, the Founders Longevity Forum will address the investment opportunities across the longevity space, from established longevity business models such as diagnostics, longevity clinics and supplements, through to cutting-edge longevity biotech companies poised to revolutionize the biotech industry and transform society. The event will also benefit from an advisory panel that has decades of longevity and geroscience expertise between them; the panel includes Eric Verdin, Andrea Maier, Jim Mellon and Aubrey de Grey, with further members to be announced. “Multiple longevity events are happening and they’re all great, but few are specifically focused on bringing more investors into this rapidly accelerating field,” said Phil Newman, Founder and CEO, Longevity.Technology “We plan to stage events in London, Abu Dhabi and San Francisco initially to accelerate longevity investment globally, and catalyze a wave of innovation and collaboration that will redefine the future of human health.” “We’re keen to educate investors on the vast opportunities in longevity whilst fostering meaningful connections for startups and scaleups in this niche,” said Carolyn Dawson, CEO, Founders Forum Group. “Helping create these connections is central to our mission at Founders Forum Group as we seek to empower entrepreneurs at every stage of their journeys; with Longevity.Technology as our partner, we can forge formative alliances that propel longevity innovation.” Key highlights of the Founders Longevity Forum: Exclusive event – The Founders Longevity Forum will host a minimum of 120 approved guests, including high-caliber investors, family offices, longevity founders and VIPs. Comprehensive program – guests will enjoy a half-day of content, a welcome reception, a full-day program and automatic registration for London Tech Week. Global reach – following the London event, the Founders Longevity Forum will travel to Abu Dhabi and San Francisco. Longevity takes center stage – The Longevity Village at London Tech Week will elevate this dynamic industry, showcasing the companies applying new technologies to extend human healthspan. |
Posted at 08/4/2024 12:04 by northeast14 None of the placing shares can be sold. And all of the people in the raise are serious investors or BOD or institutions. There will be no dumping |
Posted at 08/4/2024 09:39 by moneymunch Lol...you'll regret not buying in because of your blinkered view, the £755k raise was to facilitate the arrival of institutional investors, all the directors subscribed including £50k by Genflow's CEO....much more to come with US investors in the pipeline...this is going to big, the current bargain low and miniscule market cap offers tremendous UPside opportunity. Gl :-) |
Posted at 07/4/2024 11:02 by northeast14 It’s all beginning to point in a great direction yet again for us Steg. Really hope you get your extra cheap shares before it moves. Hopefully there will be a lot of new investors with ISA money this coming week. FDA meeting should be this quarter also. That could now be an even bigger meeting for Genflow. Hopefully it’s after the European meeting. Big Pharmaceutical will be keeping an even closer eye on us now |
Posted at 28/3/2024 13:12 by moneymunch Cheers steg, we know Eric is very keen to get institutional investors on board, and so hopefully all in the pipeline along with more positive news on proceedings. The current rockbottom low will soon be a distant memory with any luck, and I had a few first thing this morning in anticipation. Gl :-) |
Posted at 28/1/2024 09:28 by kubera369 Sharing is caring fellow investors BlackBird interviewHTTps://www |
Posted at 27/1/2024 08:54 by moneymunch Genflow Biosciences Plc 2023 Year in Review2023 was a busy and productive year for Genflow Biosciences Plc (“Genflow) marked by significant advancements in our mission to pioneer novel therapeutics for a longer, healthier life. The groundbreaking gene therapies that we are working on alongside our co-collaborators are being engineered to target both the ageing process, and reduce and delay the onset of age-related diseases. Our mission remains to lower healthcare expenditures while easing the emotional and social challenges associated with an ageing population. We’ve made numerous strategic moves this year as a part of our ongoing efforts to strengthen our company, financial and market position. Our balance sheet remains strong, and we are in a solid financial position. To comply with the updated requirements of the existing grant from the Wallonia region, and to be eligible for future grant funding, we undertook an internal debt re-organization without dilution. This puts us in a favorable financial position compared to many other biotechnology companies. We diligently continue to pursue the research, development, and safe implementation of our two pivotal programs centered on NASH (Non-Alcoholic Steatohepatitis) and Werner Syndrome and have made significant progress this year. NASH. We are pleased to report that our NASH program, which afflicts an estimated 35 million individuals worldwide and ranks among the leading causes of chronic liver disease with the urgent need for life-saving liver transplants, is progressing to plan. This program is advancing steadily, underscoring our firm commitment to combatting this pressing global health issue. In collaboration with Dr. Manlio Vinciguerra, (a Genflow Scientific Advisory Board member based at the University of Liverpool), are gaining a significantly deeper understanding of the biochemical changes that occur in the treatment of NASH using the centenarian SIRT6. This research has led to us clearly identifying the workings of our lead drug candidate, GF-1002 and its potential benefits for NASH patients. As a result, we have accumulated important data and filed a new patent application on this specific activity. Additionally, NASH clinical trials are expected to begin in Q1-Q2 2025 following dialogue and subsequent agreement with the European Medicine Agency. Werner Syndrome. Simultaneously, we are making progress targeting Werner Syndrome, an accelerated ageing disease. Here, our vision is clear: to enhance the quality of life for affected patients and expedite the path towards swift and successful first-in-human trials under orphan drug designation. Our lead compound GF-3001, is a topical delivery of SIRT6 to the skin. Key Milestones Q1 2023: Issued a shareholder update on the Company’s progress, highlighting our expanded intellectual property portfolio through a provisional patent application focusing on the ability to edit the SIRT6 gene, shown to play a role in longevity and age-related diseases as well as our solid cash position. Q2 2023: Expanded our intellectual property portfolio through a provisional patent application focusing on the ability to edit the SIRT6 gene, shown to play a role in longevity and age-related diseases. If successful, the patent will represent a significant breakthrough in the field of gene editing, with potential implications for longevity and other forms of gene therapy; Genflow started trading on the OTCQB Venture Market in the US under the ticker GENFF. This move aligns with our strategic emphasis on the US due to its significant advancements in longevity and our ongoing collaborations with US-based institutions; The Company appointed Prof. Dr. Sven Francque on our Scientific Advisory Board. Prof. Francque is currently Chairman of the Department of Gastroenterology and Hepatology of the University Hospital Antwerp and Full Professor of Medicine at the Faculty of Medicine and Health Sciences of the University of Antwerp in Belgium. He has a longstanding interest and expertise in nonalcoholic fatty liver disease and conducted [basic] research focusing on steatosis. His research unit continues to study pathophysiological mechanisms of NASH. He also conducts clinical research, and his unit is a partner in several research consortia supported by the European Commission. Q3 2023: Received positive comments from the Federal Agency for Medicines and Health Products (FAHMP) of Belgium regarding the design of our upcoming Phase I/II clinical trials of our lead drug candidate, GF-1002 with patients suffering from NASH. Following our encouraging results from in-vitro human cell and in-vivo rodent studies, the Agency concurred with Genflow’s proposal to commence clinical trials directly with NASH patients, thereby bypassing Phase I trials with healthy volunteers; Appointed Harbor Access, a strategic Investor Relations firm with offices in the US and Canada to provide investor relations support and investor outreach. Q4 2023: Appointed Capital Plus Partners Ltd (“CPP”) to act as Joint Broker, alongside Clear Capital Markets Limited. The addition of CPP is expected to bring additional expertise to the Company, strengthen our position and improve access to the capital; Appointed Prof. Dr. Mary E. Rinella, Director, Metabolic and Fatty Liver Disease Department at the University of Chicago. She has investigated a broad range of topics within fatty liver disease, including the use of non-invasive measures to minimize the use of liver biopsy and the study of new therapies to treat fatty liver disease, since there is still no FDA approved treatment. Dr. Rinella has published nearly 150 peer-review articles in prestigious journals, such as Nature Reviews Gastroenterology & Hepatology, Gastroenterology, Hepatology, Journal of the American Medical Association (JAMA), The Lancet and others. Heading into 2024, Genflow is well placed to take advantage of the recent resurgence of interest in the longevity sector. We continue to monitor opportunities, and to prioritize marketing efforts to expand our investor audience in North America and Europe. Our commitment to innovation and improving lives remains steadfast, as we navigate the opportunities and challenges that lie ahead. Together, we envision a future where our pioneering work redefines possibilities, bringing hope and transformative solutions to those who need it most. Dr. Eric Leire Founder and CEO Genflow Biosciences Plc January 25, 2024 |
Posted at 14/9/2023 18:40 by moneymunch The next Longevity Investors Conference will be held in Gstaad on September 27-29 2023About Longevity Investors Conference (LIC) The Longevity Investors Conference is bringing together the world's leading longevity key opinion leaders and scientists, institutional and private investors, wealthy private individuals, family offices, and investment funds. The main aim of the event is to discuss the latest trends and opportunities but also to provide relevant insights into the longevity and rejuvenation industry. As an investors-only conference, the event is fully focused on investors. |
Posted at 13/6/2023 07:02 by moneymunch RNS Number : 4646CGenflow Biosciences PLC 13 June 2023 Genflow Biosciences Plc ("Genflow" or "the Company") Anti-Ageing Company, Genflow Biosciences, Announces Listing on OTCQB Venture Market in addition to its LSE Main Market Listing Genflow has 3 Gene Therapies in Development Seeking to Treat NASH and Werner Syndrome Genflow Biosciences Plc ("Genflow" or "the Company") is pleased to announce that, after a successful application process, its Ordinary Shares ("Ordinary Shares") begin trading on the OTCQB Venture Market in the United States ("US") today under the symbol GENFF. Genflow will continue to trade on the London Stock Exchange ("LSE") Main Market under the symbol GENF, and, importantly, the onboarding to this additional U.S. securities trading platform does not involve any capital raise. The new U.S. trading facility expands access to a broader pool of investors and enables investors in the United States to trade during U.S. trading hours and in U.S. dollars. Eric Leire, CEO of Genflow, expressed his excitement about this significant achievement, stating, "We are thrilled to announce that Genflow Biosciences has been admitted to trading on the OTCQB Venture Market in the United States. This move not only expands our reach to a larger investor base and has the potential to enhance liquidity for our shares, but also reinforces our unwavering commitment to our primary listing on the prestigious London Stock Exchange." Tamara Joseph, Chair of the Board, also expressed her enthusiasm on behalf of the Board of Directors, saying, "Genflow is developing gene therapies that could address an important source of many global illnesses: aging. As the Company moves into Phase I/II clinical trials to treat potentially the orphan condition Werner Syndrome, which causes premature aging, and NASH, a liver disease that affects an estimated 35 million people around the world, it is the right time to retain our London Stock Exchange listing while adding easier access for US investors." Further information on Genflow's application and the OTCQB market is below: As a Foreign Private Issuer, Genflow's admission to the OTC Markets is subject to meeting the requirements for OTCQB, which apply to international reporting companies. This includes fulfilling the criteria for exemption under the US Exchange Act Rule 12g3-2(b) from SEC reporting. The Rule 12g3-2(b) exemption includes the disclosure obligation to ensure that certain information made public or distributed under home market regulations is made publicly available on the Company's website or other electronic information delivery system in English. Thus, the Company will have no additional reporting obligations and incur minimal ongoing costs; admission to the OTC Markets is subject to meeting the requirements for OTCQB, which apply to international reporting companies. This includes fulfilling the criteria for exemption under the US Exchange Act Rule 12g3-2(b) from SEC reporting. Under this exemption, the Company must ensure that information made public or distributed under its home market regulations is made available to the public on its website or another electronic information delivery system in English. Consequently, Genflow will have no additional reporting obligations and will incur minimal ongoing costs compared to traditional major exchanges. As a verified market, the OTCQB offers transparent trading for companies that have met a minimum bid price test, are current in their financial reporting and have undergone an annual verification and management certification process. The cross-trading facility is provided through OTC Markets Group Inc., located in New York. OTC Markets operates the world's largest electronic interdealer quotation system for US broker-dealers and offers multiple media channels to increase the visibility of OTC-listed companies. Online brokers such as Ameritrade, Fidelity Investments, Tradestation, Charles Schwab and E-trade all offer OTCQB trades. US investors can find real-time quotes, market information and access current company news and developments on a BSF page on the OTC Markets website at www.otcmarkets.com. Genflow appointed the corporate securities law firm Galanopoulos & Company as its OTCQB Sponsor to support its onboarding to the OTCQB Venture Market. Additional information about the OTCQB market can be found at: www.otcmarkets.com/l The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
